Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227250 | 1.00 | DRD2 (0.45) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL18896411 | 0.92 | BTK (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL15688768 | 0.92 | BTK (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL27181833 | 0.91 | DRD2 (0.42) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL27181835 | 0.91 | DRD2 (0.42) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL25042067 | 0.87 | SMYD3 (0.46) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL31205818 | 0.87 | SMYD3 (0.46) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL15285429 | 0.87 | BTK (0.44) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL21211377 | 0.87 | BTK (0.44) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL912304 | 0.87 | DRD2 (0.47) | DRD2BTKEPHX1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718795-B2 | 1,4-cyclohexylamine derivatives and processes for the preparation thereof | CHEMO RESEARCH, S.L. (ES) | 2017-08-01 | — | — | US | disclosed |
| US-9718795-B2 | 1,4-cyclohexylamine derivatives and processes for the preparation thereof | CHEMO RESEARCH, S.L. (ES) | 2017-08-01 | — | — | US | disclosed |
| EP-3057942-B1 | 1,4-CYCLOHEXYLAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CHEMO RES S L (ES) | 2017-06-14 | — | — | EP | disclosed |
| US-20160257661-A1 | 1,4-CYCLOHEXYLAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CHEMO RESEARCH, S.L. (ES) | 2016-09-08 | — | — | US | disclosed |
| US-20160257661-A1 | 1,4-CYCLOHEXYLAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CHEMO RESEARCH, S.L. (ES) | 2016-09-08 | — | — | US | disclosed |
| WO-2015056164-A1 | 1,4-CYCLOHEXYLAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CHEMO RESEARCH, S.L. (ES) | 2015-04-23 | — | — | WO | disclosed |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HOFFMAN-LA ROCHE INC. | 2014-11-27 | — | — | US | disclosed |
| US-8829029-B2 | Dual modulators of 5HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2183245-B1 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-07-09 | — | — | EP | disclosed |
| US-20130165432-A1 | Dual Modulators of 5HT2A and D3 Receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20100075983-A1 | D3 AND 5-HT2A RECEPTOR MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
| WO-2010031735-A1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009019174-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013212-A2 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| EP-1987019-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165432-A1 | Dual Modulators of 5HT2A and D3 Receptors | HTR2A, HTR3A, HTR1A | DRD2 6/4885BTK 3511/4885EPHX1 2343/4885 |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | DRD2 16/4885BTK 3933/4885EPHX1 2182/4885 |
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR5A | DRD2 6/4885BTK 3640/4885EPHX1 2709/4885 |
| US-20160257661-A1 | 1,4-CYCLOHEXYLAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CYP4Z1, PNMT, HTR5A | DRD2 20/4885BTK 4369/4885EPHX1 841/4885 |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HTR2A, HTR3A, HTR1A | DRD2 6/4885BTK 3511/4885EPHX1 2343/4885 |
| US-20100075983-A1 | D3 AND 5-HT2A RECEPTOR MODULATORS | HTR2A, HTR3A, HTR1A | DRD2 7/4885BTK 2939/4885EPHX1 2347/4885 |
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | DRD2 59/4885BTK 3625/4885EPHX1 360/4885 |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR1A | DRD2 6/4885BTK 3511/4885EPHX1 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.